Open Orphan #ORPH – Major New Contract Signed With US Biotech Company for RSV Human Study & CEO Trevor Phillips to Step Down. May 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce the signing of a new contract with a US biotechnology Company for the provision of a respiratory syncytial virus (RSV) human challenge study. Highlights: Challenge study projected to deliver £3.5 million in revenue in 2020…

Race to stop the world getting sick: As coronavirus ravages the globe, experts work around the clock developing vaccines and trialling drugs in a desperate attempt to contain it March 24, 2020 – Posted in: Open Orphan (ORPH)

by Pat Hagan, Daily Mail As the needle slipped into Jennifer Haller’s arm, the world watched and held its breath. This was the moment last week when Jennifer became the first person to be injected with an experimental vaccine that scientists hope will help prevent future pandemics of the deadly Covid-19 coronavirus. Mother-of-two Jennifer, 43, from Seattle, told reporters: ‘We all feel so helpless. But this is an amazing opportunity for me to do something.’…

Wanted: People Willing to Get Sick to Find Coronavirus Vaccine March 19, 2020 – Posted in: Open Orphan (ORPH)

British lab is recruiting volunteers for study it says could speed development of Covid-19 vaccine By Denise Roland March 19, 2020 7:00 am ET Thousands of people have volunteered to be infected in the hope of finding a vaccine for the new coronavirus. hVIVO, a clinical research group in London, has attracted more than 20,000 volunteers willing to be infected with tamer relatives of the virus that causes Covid-19 in exchange for a fee of…

Open Orphan #ORPH – Development of the World’s First Human Coronavirus Challenge Study Model March 9, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan, the rapidly growing specialist Clinical Research Organisation (“CRO”) pharmaceutical services company whose London-based subsidiary hVIVO is the world leader in the provision of virology and vaccine challenge study services, is pleased to announce that it has commenced the development of the world’s first commercial human coronavirus challenge study model, also known as a Controlled Human Infection Model (CHIM). The Company has Europe’s only 24-bedroom quarantine clinic with onsite virology lab where the challenge model…

Shares Magazine Spotlight – Open Orphan lining up for coronavirus fight February 27, 2020 – Posted in: Open Orphan (ORPH)

Built to sell – can dealmaker Cathal Friel build (and sell) a £80m company in two years? February 24, 2020 – Posted in: Open Orphan (ORPH)

by Sean Keyes | Financial Correspondant Serial dealmaker Cathal Friel has an audacious plan: build and sell a pharma services company in two years. It could fetch as much as £100 million. What exactly is his plan? And will it work? On the cover of the fifth edition of Dr John Oxford’s book Human Virology is a picture of the Wuhan strain of the coronavirus. It was published in 2016. The virus spherical, with hundreds…

Open Orphan (ORPH) Appoints Professor Oxford as Chair of Advisory Board, with initial focus to help guide Open Orphan in the provision of solutions to Coronavirus outbreak February 20, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe’s only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London, is pleased to announce the appointment of Professor John Oxford as Chair of a newly established Advisory Board. The Advisory Board will focus initially on guiding Open Orphan…

LSE interview – Cathal Friel refocuses Open Orphan #ORPH as he raises 5m and buys virology specialist hVIVO February 7, 2020 – Posted in: Open Orphan (ORPH)

In a wide-ranging interview with London South East, Open Orphan Executive Chairman Cathal Friel outlines his vision for the business and explains how the combined talents of Open Orphan, hVivo and Venn Life Sciences will create a soon to be profitable pharmaceutical services one-stop shop. Friel says this acquisition is the last however, as he is a major shareholder and he doesn’t want to see his own shareholding diluted along with everyone elses. The focus…

BRR Media – Open Orphan #ORPH introduces Professor John Oxford – Posted in: Open Orphan (ORPH)

BRR Media introduces Open Orphan’s Professor John Oxford, consultant to the company and Virology expert. He discusses virology, and looks at recent virus epidemics, including influenza, AIDS, SARS and now Coronavirus. He explains how the hHIVO quarantine unit could play a key role in defeating Coronavirus…”This group (Open Orphan) is perfectly positioned, probably like no other, to move virology forward…particularly respiratory virology..” Click on the image to watch

Proactive Investors interview with the Open Orphan #ORPH team on its future and ‘the lottery ticket’ sitting within hVIVO February 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan PLC‘s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott following the completion last week of its £5.3mln fundraise. Also in studio is adviser to Open Orphan and founder of hVivo Professor John Oxford. Professor Oxford’s been a leader in the field of vaccine and anti-viral clinical trials for the last 20 years. hVivo, which has recently been acquired by Open Orphan, owns the largest commercial quarantine clinic in northern Europe and…